Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a puff of cannabis stop a migraine? small study investigates

NCT ID NCT05427630

Symptom relief Sponsor: University of California, San Diego Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused This study
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tested three different strengths of inhaled cannabis (2.5%, 5%, and 10% THC) against a placebo to see if they could quickly relieve migraine headaches. Twenty adults with migraine took part in a crossover design, meaning each person tried all options. The main goal was pain freedom two hours after treatment, along with relief from the most bothersome symptom like nausea or light sensitivity. The study was suspended, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Inhaled cannabis flower (THC 2.5%, 5%, 10%)
What this could lead to
If it works, this could point toward a fast-acting, plant-based option for easing migraine pain and related symptoms like nausea or light sensitivity.
What could go wrong
This is a very small pilot study (20 people) that was suspended, so results may not be reliable or generalizable. Cannabis can cause side effects like dizziness or anxiety, and its long-term effects on migraine are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2023

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 21 and ≤ 65 * Able to communicate in English * Migraine, with or without aura, in its episodic or chronic manifestations, as per the International Headache Society (IHS) classification International Classification of Headache Disorders (ICHD-3) criteria (section 1.1, 1.2, 1.3).(48) * Ability to provide informed consent and complete website questionnaires in English * Agrees not to use cannabis outside of the study during participation in the study * Agrees not to use opioids or barbiturates during participation in the study * Agrees not to drive a motor vehicle within 4.5 hours following last use of inhaled cannabis during participation in the study Exclusion Criteria: * Positive urine drug test for THC, barbiturates, opioids, oxycodone, or methadone prior to enrollment * Pregnancy * Breastfeeding * Prisoner * Known cognitive impairment * Institutionalized * Current moderate-severe or severe depression * Current or past history of bipolar depression, schizophrenia, or psychosis * Current or past history of cannabis, alcohol, opioid, or amphetamine abuse or other substance use disorder at the discretion of the research team * Active pulmonary disease, class IV heart failure, cirrhosis, or other severe medical illnesses at the discretion of the research team. * Allergy to cannabis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cannabis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cannabis dependence migraine disorder thrombocytopenia 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cannabis Migraine THC

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Center for Pain Medicine, UC San Diego

    La Jolla, California, 92037, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.